Vaccine Design pp 297-311 | Cite as

Development of Vaccines Based on Formulations Containing Nonionic Block Copolymers

  • Robert N. Brey
Part of the Pharmaceutical Biotechnology book series (PBIO, volume 6)


This chapter focuses on the capacity of vaccine formulations containing synthetic nonionic block polymers to modify or augment immune responses to current vaccines and some vaccines under development. These polymers are surface-active agents that can be formulated alone with antigens or as part of hydrophobic delivery vehicles. In current licensed human vaccines, improvements can be made to increase vaccine immunogenicity so that they can be administered in fewer injections, or so that seroconversion rates can be increased in target populations. Subunit antigen vaccines under development can lack potency, which can be significantly enhanced if formulated with an adjuvant or given in the appropriate delivery system. The capacity to induce a protective immune response can be induced by incorporating immunogens into delivery systems. These delivery systems include molecules and preparations classified as adjuvants, antigen encapsulation strategies, antigen targeting techniques, pulsatile release vehicles, live vectors, and other systems.


Influenza Vaccine Triblock Copolymer Seroconversion Rate Vaccine Formulation Adjuvant Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G., and Scott, P., 1994, The adjuvant effect of interleukin-12 in a vaccine against Leishmania major, Science 263:235–237.PubMedCrossRefGoogle Scholar
  2. Allison, A. C., and Byars, N. E., 1990, Adjuvant formulations and their mode of action, Semin. Immunol. 2:369–374.PubMedGoogle Scholar
  3. Alving, C. R., 1993, Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants, Immunobiology 187:430–446.PubMedCrossRefGoogle Scholar
  4. Alving, C. R., Verma, J. N., Rao, M., Krzych, U., Amselem, S., Green, S. M., and Wassef, N. M., 1992, Liposomes containing lipid A as a potent non-toxic adjuvant, Res. Immunol. 143:197–198.PubMedCrossRefGoogle Scholar
  5. Audibert, F. M., and Lise, L. D., 1993, Adjuvants: Current status, clinical perspectives and future prospects, Immunol. Today 14:281–284.PubMedCrossRefGoogle Scholar
  6. Butterly, L., Watkins, E., and Dienstag, J. L., 1989, Recombinant-yeast derived hepatitis B vaccine in healthy adults: Safety and two-year immunogenicity of early investigative lots of vaccine, J. Med. Virol. 27:155–159.PubMedCrossRefGoogle Scholar
  7. Byars, N. E., Allison, A. C., Harmon, M. W., and Kendal, A. P., 1990, Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation, Vaccine 8:49–56.PubMedCrossRefGoogle Scholar
  8. Byars, N. E., Nakano, G., Welch, M., Lehman, D., and Allison, A. C., 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine 9:309–318.PubMedCrossRefGoogle Scholar
  9. Chu, C. T., and Pizzo, S. V., 1993, Receptor-mediated antigen delivery into macrophages, J. Immunol. 150:48–58.PubMedGoogle Scholar
  10. Clerici, M., Lucey, D. R., Berzovsky, J.A., Pinto, L. A., Wynn, T. A., Blatt, S. A., Dolan, M. J., Hendrix, C. W., Wolf, S.W., and Shearer, G. M., 1993, Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro, Science 262:1721–1724.PubMedCrossRefGoogle Scholar
  11. Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R. M., 1991, Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin neutralizing antibodies, Infect. Immun. 59:2978–2986.PubMedGoogle Scholar
  12. Germain, R. N., and Margulies, D. H., 1993, The biochemistry and cell biology of antigen processing and presentation, Annu. Rev. Immunol. 11:403–540.PubMedCrossRefGoogle Scholar
  13. Ghalib, H. W., Piuvezam, M. R., Skeiky, Y. A., Siddig, M., Hashim, F. A., el Hassan, A., Russo, D. M., and Reed, S. G., 1993, Interleukin 10 production correlates with pathology in human Leishmania donovani infections, J. Clin. Invest. 92:324–329.PubMedCrossRefGoogle Scholar
  14. Good, M. F., Pombo, D., Lunde, M. N., Maloy, W. L., Halenbeck, R., Koths, K., Miller, L. H., and Berzofsky, J. A., 1988a, Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2, J. Immunol. 141:972–977.PubMedGoogle Scholar
  15. Good, M. F., Pombo, D., Quakyi, I. A., Riley, E. M., Houghten, R. A., Menon, A., Alling, D. W., Berzofsky, J. A., and Miller, L. H., 1988b, Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule, Proc. Natl. Acad. Sci. USA 85:1199–1203.PubMedCrossRefGoogle Scholar
  16. Haigwood, N. L., Nara, P. L., Brooks, E., Van Nest, G., Ott, G., Higgins, K. W., Dunlop, N., Scandella, C. J., Eichberg, J. W., and Steimer, K. S., 1992, Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons, J. Virol. 66:172–182.PubMedGoogle Scholar
  17. Hilleman, M. R., 1967, Considerations for safety and application of emulsified oil adjuvants to viral vaccines, in: International Symposium on Adjuvants of Immunity, Utrecht, 1966, Karger, Basel, pp. 13–26.Google Scholar
  18. Hilleman, M. R., Woodhur, A., and Friedman, A., 1972, The clinical application of adjuvant 65, Ann. Allergy 30:152–158.PubMedGoogle Scholar
  19. Howerton, D. A., Hunter, R. L., Ziegler, H. K., and Check, I. J., 1990, Induction of macrophage Ia expression in vivo by a synthetic block polymer, L81, J. Immunol. 144:1578–1584.PubMedGoogle Scholar
  20. Hunter, R. L., and Bennett, B., 1984, The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers, J. Immunol. 133:3167–3175.PubMedGoogle Scholar
  21. Hunter, R. L., and Bennett, B., 1986, The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces, Scand. J. Immunol. 23:287–300.PubMedCrossRefGoogle Scholar
  22. Hunter, R. L., Strickland, F., and Kezdy, F., 1981, The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance, J. Immunol. 127:1244–1250.PubMedGoogle Scholar
  23. Hunter, R., Olsen, M., and Buynitzky, 1991, Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody, Vaccine 9:250–256.PubMedCrossRefGoogle Scholar
  24. Hunter, R. L., Kidd, M. R., Olsen, M. R., Patterson, P. S., and Lal, A. A., 1994, Induction of long-lasting immunity to P. yoelii malaria using whole blood-stage antigen and copolymer adjuvants, (submitted).Google Scholar
  25. Inselburg, J., Bathurst, I. C., Kansopon, J., Barr, P. J., and Rossan, R., 1993, Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: Further studies using SERA1 and MF75.2 adjuvant, Infect. Immun. 61:2048–2052.PubMedGoogle Scholar
  26. Institute of Medicine Committee on the Children’s Vaccine Initiative, 1993, The Children’s Vaccine Initiative (V. S. Mitchell, N. M. Philipose, and J. P. Sanford, eds.), National Academy Press, Washington, DC.Google Scholar
  27. Kalish, M. L., Check, I. J., and Hunter, R. L., 1991, Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG)5, J. Immunol. 146:3583–3590.PubMedGoogle Scholar
  28. Keitel, W., Couch, R., Bond, N., Adair, S., Van Nest, G., and Dekker, C., 1993, Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant, Vaccine 11:909–913.PubMedCrossRefGoogle Scholar
  29. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D., 1991, Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex, J. Immunol. 146:431–437.PubMedGoogle Scholar
  30. Lanzavecchia, A., 1993, Identifying strategies for immune intervention, Science 260:937–944.PubMedCrossRefGoogle Scholar
  31. Livingston, P. O., Adluri, S., Raychaudhuri, S., Hughes, M. H., Calves, M. J., and Merritt, J. A., 1994, A phase I trial of the immunological adjuvant SAFm in melanoma patients vaccinated with the anti-idiotype antibody MELIMMUNE™, Vaccine Res. 3:71–81.Google Scholar
  32. Meuer, S. C., 1989, Low dose interleukin-2 induces systemic immune response against HBsAg in immunodeficient non-responders to hepatitis B vaccination in dialysis patients, Lancet 1:15–18.PubMedCrossRefGoogle Scholar
  33. Millet, P., Kalish, M. L., Collins, W. E., and Hunter, R. L., 1992, Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine, Vaccine 10:547–550.PubMedCrossRefGoogle Scholar
  34. Mosmann, T. R., and Coffman, R. L., 1989, TH1 and TH2 cells: Different pattern of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol. 7:145–173.PubMedCrossRefGoogle Scholar
  35. Page, W. F., Norman, J. E., and Benenson, A. S., 1993, Long-term follow-up of army recruits immunized with Freund’s incomplete adjuvanted vaccine, Vaccine Res. 2:141–149.Google Scholar
  36. Potter, C. W., Jennings, R., Phair, J. P., Clarke, A., and Stuart-Harris, C. H., 1977, Dose-response relationship after immunization of volunteers with a new, surface antigen-adsorbed influenza virus vaccine, J. Infect. Dis. 135:423–431.PubMedCrossRefGoogle Scholar
  37. Raychaudhuri, S., Tonks, M., Carbone, F., Ryskamp, T., and Morrow, J.W., 1992, Induction of antigen-specific class I-restricted cytotoxic T cells by soluble protein in vivo, Proc. Natl. Acad. Sci. USA 89:8308–8312.PubMedCrossRefGoogle Scholar
  38. Rock, K. L., Fleischacker, G., and Gamble, S., 1993, Peptide-priming of cytolytic T cell immunity in vivo using β2-microglobulin as an adjuvant, J. Immunol. 150:1244–1252.PubMedGoogle Scholar
  39. Sanchez-Pescador, L., Burke, R. L., Ott, G., and Van Nest, G., 1988, The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine, J. Immunol. 141:1720–1727.PubMedGoogle Scholar
  40. Schirmbeck, R., Melber, K., Kuhrober, A., Janowicz, Z. A., and Reimann, J., 1994, Immunization with soluble hepatitis B virus specific surface protein elicits murine H-2 class-I restricted cytotoxic T lymphocyte responses in vivo, J. Immunol. 152:1110–1119.PubMedGoogle Scholar
  41. Scott, P., 1991, IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis, J. Immunol. 147:3149–3155.PubMedGoogle Scholar
  42. Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A., 1989, Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease, Immunol. Rev. 112:161–182.PubMedCrossRefGoogle Scholar
  43. Sempertegui, F., Estrella, B., Moscoso, J., Piedrahita, L., Hernandez, D., Gaybor, J., Naranjo, P., Mancero, O., Arias, S., Bernai, R., Cordova, M. E., Suarez, J., and Zicker, F., 1994, Safety, immunogenicity and protective effect of SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador, Vaccine 12:337–342.PubMedCrossRefGoogle Scholar
  44. Skea, D. L., and Barber, B. H., 1993, Adhesion-mediated enhancement of the adjuvant activity of alum, Vaccine 11:1018–1026.PubMedCrossRefGoogle Scholar
  45. Takayama, K., Olsen, M., Datta, P., and Hunter, R. L., 1991, Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors, Vaccine 9:257–265.PubMedCrossRefGoogle Scholar
  46. ten Hagen, T. L. M., Sulzer, A. J., Kidd, M. R., Lal, A. A., and Hunter, R. L., 1993, Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines, J. Immunol. 151:7077–7085.PubMedGoogle Scholar
  47. Teusher, T., Armstrong-Schellenberg, J. R. M., Bastos de Azvedo, I., Hurt, N., Smith, T., Hayes, R., Masanja, H., Silva, Y., Lopez, M. C., Kitua, A., Kilama, W., Tanner, M., and Alonzo, P. L., 1994, SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission, Vaccine 12:328–336.CrossRefGoogle Scholar
  48. Townsend, A., and Bodmer, H., 1989, Antigen recognition by class I-restricted T lymphocytes, Annu. Rev. Immunol. 7:601–624.PubMedCrossRefGoogle Scholar
  49. Van Dam, GJ., Verheul, A. F. M., Zigterman, G. J. W. J., De Reuver, M. J., and Snippe, H., 1989, Nonionic block polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 2 in normal and Xid mice, J. Immunol. 143:3049–3053.PubMedGoogle Scholar
  50. Van de Wijgert, J. H. H. M., Verheul, A. F. M., Snippe, H., Check, I. J., and Hunter, R. L., 1991, Immunogenicity of Streptococcus pneumoniae type 14 capsular Polysaccharide: Influence of carriers and adjuvants on isotype distribution, Infect. Immun. 59:2750–2757.PubMedGoogle Scholar
  51. Weissman, J. Y., Tsuchiyose, M. M., Tong, M. J., Co, R., Chin, K., and Ettenger, R. B., 1988, Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine, J. Am. Med. Assoc. 260:1734–1738.CrossRefGoogle Scholar
  52. Wintsch, J., Chaignat, C.-L., Braun, D.G., Jeannet, M., Stadler, H., and Abrignanai, S., 1991, Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine, J. Infect. Dis. 163:219–225.PubMedCrossRefGoogle Scholar
  53. Zigterman, G. J. W. J., Snippe, H., Jansze, M., and Willers, J. M. N., 1987, Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response, J. Immunol. 138:220–225.PubMedGoogle Scholar
  54. Zigterman, G. J. W. J., Snippe, H., Jansze, M., Ernste, E. B. H. W., De Reuver, M. J., and Willers, J. M. N., 1988, Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharideconjugate vaccines, Infect. Immun. 56:1391–1393.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Robert N. Brey
    • 1
  1. 1.Vaxcel, Inc.NorcrossUSA

Personalised recommendations